For tapentadol, only two in the three randomized managed trials executed up to now in diabetic peripheral neuropathy have concluded that tapentadol is exceptional to placebo [64, seventy two]. On the basis from the available details, its efficacy In this particular indication was regarded inferior to that of tramadol, and probably overestimated by